Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced the presentation of data from studies evaluating the
companys investigational oral chronic hepatitis C virus (HCV)
treatments MK-5172 and MK-8742 at the 64th American
Association for the Study of Liver Diseases Annual Meeting (AASLD). The
meeting is scheduled to take place in Washington, D.C., Nov. 1-5, 2013.
Language:
English
Contact:
MerckMedia:Sarra Herzog, 908-423-6154orInvestor:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more